Nasdaq
$88.02▼ 1.33%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $6.03BShares out 68.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 10.13Regular26.10.14 02:37SCHEDULE 13GOwnership#●●●#●●●
RHYTHM PHARMACEUTICALS, INC.
JPMorgan Chase & Co. has filed a Schedule 13G, disclosing a beneficial ownership of more than 5% in Rhythm Pharmaceuticals, Inc. This filing indicates a change in the institution's stake in the company, which is a key development for investors to monitor.…more
$88.02-1.33%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.14After-hours26.09.15 08:374Ownership
RHYTHM PHARMACEUTICALS, INC.
David P. Meeker of Rhythm Pharmaceuticals reported a change in beneficial ownership of company securities as of September 14, 2026. This filing serves as a standard disclosure regarding the executive's stock holdings.…more
$88.02-1.33%vs prev closeView filingShare - 9.14After-hours26.09.15 05:49144Ownership
RHYTHM PHARMACEUTICALS, INC.
David P. Meeker of Rhythm Pharmaceuticals has filed an SEC Form 144 to report a proposed sale of company shares. This filing serves as a notification of the insider's intent to dispose of stock.…more
$88.02-1.33%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.21 21:00#●●●#●●●
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 3…more
Rhythm Pharmaceuticals announced it will release its third quarter 2026 financial results and provide a corporate update on November 3, 2026. The company also plans to participate in upcoming investor conferences to discuss its business progress.…more
$88.02-1.33%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14Overnight26.10.14 15:10
●●●●●●●● ●●●●● ●●●●●●
Rhythm Pharmaceuticals has launched IMCIVREE in Japan as the first approved therapy for acquired hypothalamic obesity. The launch follows positive Phase 3 trial results demonstrating an 18.8% placebo-adjusted reduction in BMI.…more
$88.02-1.33%vs prev closeShareBenzinga - 10.13After-hours26.10.14 08:30
●●●●●●●● ●●●●● ●●●●●●
Rhythm Pharmaceuticals has officially launched its acquired hypothalamic obesity treatment, IMCIVREE, in the Japanese market. Following its inclusion on the National Health Insurance drug price list, the company is beginning commercial distribution in the region.…more
$88.02-1.33%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report